Is Esperion Therapeutics Inc. (ESPR) Price Targeted To Increase?

As of Friday close, Esperion Therapeutics Inc.’s (NASDAQ:ESPR) stock was up $0.18, moving up 3.04 percent to $6.10. The average number of shares traded per day over the past five days has been 1,321,760 shares. 3 times new highs have been achieved over the past 5 days, with a $0.33 gain in that time frame. In the last twenty days, the average volume was 685,725, while in the previous 50 days, it was 762,960.

Since last month, ESPR stock retreated -7.01%. Shares of the company fell to $5.28 on 08/01/22, the lowest level in the past month. A 52-week high of $15.05 was reached on 07/06/22 after having rallying from a 52-week low of $3.28. Since the beginning of this year, ESPR’s stock price has risen by 22.00% or $1.10, and marked a new high 16 times. However, the stock has declined by -59.47% since its 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Esperion Therapeutics Inc. (ESPR) last reported insider trading activity 18 days ago on Jul 19. Foody Joanne M., the Chief Medical Officer of the company, disposed of 3,901 shares for $6.55 on Jul 19. It resulted in a $25,552 divestment by the insider. Warren Eric sold 431 shares at an average price of $6.58 on Jul 19. The insider now owns 53,223 shares following the transaction. On Jun 17, President and CEO Koenig Sheldon L. sold 4,552 shares at $4.99 apiece. The transaction was valued at $22,719.

Financial Health

In the three months ended March 30, Esperion Therapeutics Inc.’s quick ratio stood at 3.20, while its current ratio was 3.70, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 78.10% percent. Based on annual data, ESPR earned $64.23 million in gross profit and brought in $78.45 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -369.30%. Return on equity (ROE) for the past 12 months was 84.40%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ESPR’s revenue fell -115.82% to $18.84 million during the quarter, while net income inched up to $18.84 million. While analysts expected Esperion Therapeutics Inc. to report -$1.04 quarterly earnings, the actual figure was -$0.93 per share, beating the consensus estimate by 10.60%. During the quarter, the company generated -$51.62 million in EBITDA. The liabilities of Esperion Therapeutics Inc. were 595.68 million at the end of its most recent quarter ended March 30, and its total debt was $527.0 million. The value of shareholders’ equity is $66.55 million.

Technical Picture

This quick technical analysis looks at Esperion Therapeutics Inc.’s (ESPR) price momentum. With a historical volatility rate of 64.23%, the RSI 9-day stood at 50.70% on 05 August.

With respect to its five-day moving average, the current Esperion Therapeutics Inc. price is up by +5.72% percent or $0.33. At present, ESPR shares trade -8.55% below its 20-day simple moving average and +28.69% percent above its 100-day simple moving average. However, the stock is currently trading approximately +5.35% above its SMA50 and -36.13% below its SMA200.

Stochastic coefficient K was 40.19% and Stochastic coefficient D was 33.73%, while ATR was 0.40. Given the Stochastic reading of 50.78% for the 14-day period, the RSI (14) reading has been calculated as 49.61%. As of today, the MACD Oscillator reading stands at 0.03, while the 14-day reading stands at -0.16.

Analyst Ratings

Esperion Therapeutics Inc. downgraded its rating on Esperion Therapeutics Inc. (NASDAQ: ESPR) to an Underperform in a note to investors on August 03, 2022. The analysts firm previously had a Neutral rating on the stock.Esperion Therapeutics Inc. (ESPR) has been rated Hold by analysts. According to 3 brokerage firms, ESPR is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Esperion Therapeutics Inc. stock as buy, with 5 recommending it as overweight.

With a median target price of $7.00, the current consensus forecast for the stock is $3.00 – $22.00. Based on these forecasts, analysts predict Esperion Therapeutics Inc. (ESPR) will achieve an average price target of $10.27.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]